[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 53, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 57, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 594612, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 339819, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 48, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 365556, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 53, "title": "Chief Corporate & Business Development Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 339300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 63, "title": "Chief Commercial Officer, President of RedHill Biopharma Inc. & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 469802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Senior Business Development & Investor Relations Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Reza  Fathi Ph.D.", "age": 68, "title": "Senior Vice President of Research & Development", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 299291, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Goldberg J.D.", "age": 47, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 338126, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.75, "open": 10.75, "dayLow": 10.2, "dayHigh": 10.75, "regularMarketPreviousClose": 10.75, "regularMarketOpen": 10.75, "regularMarketDayLow": 10.2, "regularMarketDayHigh": 10.75, "beta": 3.674, "forwardPE": 344.6667, "volume": 17150, "regularMarketVolume": 17150, "averageVolume": 331758, "averageVolume10days": 61240, "averageDailyVolume10Day": 61240, "bid": 9.98, "ask": 10.58, "bidSize": 100, "askSize": 100, "marketCap": 13240784, "fiftyTwoWeekLow": 6.425, "fiftyTwoWeekHigh": 82.0, "priceToSalesTrailing12Months": 3.5718327, "fiftyDayAverage": 9.971, "twoHundredDayAverage": 15.68875, "currency": "USD", "enterpriseValue": 126418223104, "floatShares": 11087173665, "sharesOutstanding": 1280540, "sharesShort": 120468, "sharesShortPriorMonth": 16697, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0941, "heldPercentInstitutions": 0.11533, "shortRatio": 0.15, "shortPercentOfFloat": 0.1062, "bookValue": 0.052, "priceToBook": 198.84615, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -30174000, "trailingEps": -302.63, "forwardEps": 0.03, "enterpriseToRevenue": 34102.57, "enterpriseToEbitda": -6036.876, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RDHL", "underlyingSymbol": "RDHL", "shortName": "Redhill Biopharma Ltd.", "longName": "RedHill Biopharma Ltd.", "firstTradeDateEpochUtc": 1357569000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "55b47776-7c51-3ec7-bc27-c300c5d6081d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.34, "targetHighPrice": 19000.0, "targetLowPrice": 19000.0, "targetMeanPrice": 19000.0, "targetMedianPrice": 19000.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 7277000, "totalCashPerShare": 0.001, "ebitda": -20941000, "totalDebt": 558000, "quickRatio": 0.389, "currentRatio": 0.74, "totalRevenue": 3707000, "debtToEquity": 914.754, "revenuePerShare": 4.733, "returnOnAssets": -0.44882, "returnOnEquity": -17.086071, "freeCashflow": -5386000, "operatingCashflow": -24230000, "revenueGrowth": -0.284, "grossMargins": 0.34043998, "operatingMargins": -3.2846, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-17"}]